Stock Analysis

Kuros Biosciences Full Year 2022 Earnings: CHF0.43 loss per share (vs CHF0.23 loss in FY 2021)

Source: Shutterstock

Kuros Biosciences (VTX:KURN) Full Year 2022 Results

Key Financial Results

  • Revenue: CHF18.0m (up 30% from FY 2021).
  • Net loss: CHF14.6m (loss widened by 94% from FY 2021).
  • CHF0.43 loss per share (further deteriorated from CHF0.23 loss in FY 2021).
SWX:KURN Earnings and Revenue History March 17th 2023

All figures shown in the chart above are for the trailing 12 month (TTM) period

Kuros Biosciences shares are down 18% from a week ago.

Risk Analysis

We should say that we've discovered 3 warning signs for Kuros Biosciences (1 can't be ignored!) that you should be aware of before investing here.

Valuation is complex, but we're helping make it simple.

Find out whether Kuros Biosciences is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis